Pko Investment Management Joint Stock CO Editas Medicine, Inc. Transaction History

Pko Investment Management Joint Stock CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Mar 13, 2025	SELL	$31.4 - $41.01 $2.47 Million - $3.22 Million	-78,559 Reduced 40.83%	113,833 $4.08 Billion
Q1 2018 Mar 13, 2025	BUY	$29.84 - $44.08 $1.24 Million - $1.83 Million	41,500 Added 27.5%	192,392 $6.38 Billion
Q4 2017 Mar 13, 2025	BUY	$21.89 - $31.34 $1.15 Million - $1.65 Million	52,590 Added 53.5%	150,892 $4.64 Billion
Q3 2017 Mar 13, 2025	BUY	$15.81 - $24.01 $1.39 Million - $2.11 Million	87,963 Added 850.79%	98,302 $2.36 Billion
Q2 2017 Mar 13, 2025	BUY	N/A	10,339	10,339 $173 Million

228

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $87.3M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Pko Investment Management Joint Stock CO, based on Form 13F filings with the SEC.

Stay updated on Pko Investment Management Joint Stock CO with notifications on news.